HER2 positivity is not associated with adverse prognosis in high-risk estrogen receptor-positive early breast cancer patients treated with chemotherapy and trastuzumab

HER2 positivity is not associated with adverse prognosis in high-risk estrogen receptor-positive early breast cancer patients treated with chemotherapy and trastuzumab

Co-expression of human epidermal growth factor receptor-2 (HER2) and hormone receptor (HR) predicted worse prognosis in early breast cancer before trastuzumab was developed. We aimed to investigate whether HER2 positivity was still associated with worse outcome in high-risk estrogen receptor (ER) po...

Full description

Bibliographic Details
Main Authors: Shuai Li, Jiayi Wu, Ou Huang, Jianrong He, Li Zhu, Weiguo Chen, Yafen Li, Xiaosong Chen, Kunwei Shen
Format: Article
Language:English
Published: Elsevier 2020-12-01
Series:Breast
Subjects:
Breast neoplasms
Prognosis
Receptor
ErbB-2
Receptors
Estrogen
Online Access:http://www.sciencedirect.com/science/article/pii/S0960977620301934

Internet

http://www.sciencedirect.com/science/article/pii/S0960977620301934

Similar Items